Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Outcomes of CAR T-cell therapies after prior treatment with fixed-duration mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

DTDimitrios TzachanisSYShen YinQZQian Zhu

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows CAR T-cell therapies maintain efficacy post-mosunetuzumab in relapsed/refractory B-cell lymphoma, highlighting a viable treatment path.

Key Points

  • This analysis aims to evaluate the effects of prior mosunetuzumab treatment on the outcomes of CAR T-cell therapies in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
  • Conducted a retrospective, multicenter case series evaluation of patients previously treated with mosunetuzumab.
  • Included patients from the Phase I/II clinical trial who received CAR T-cell therapy following mosun treatment.
  • Analyzed efficacy and safety outcomes with reported responses to CAR T-cell therapy.
  • Among the analyzed patients, complete response rates were observed in various lymphoma subtypes: 87.5% in large B-cell, 40% in mantle cell, and 100% in follicular lymphoma.
  • Cytokine release syndrome occurred in 68.2% with low grade severity, while immune effector cell-associated neurotoxicity was noted in 36.4% of patients.
  • Median age of participants was 67 years, with 54.5% receiving CAR T-cell therapy as their last line of treatment.

Cite This Study

Tzachanis et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236debehttps://doi.org/10.1182/blood-2025-6261
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study2025 · 1 citations
  2. 2Real-world outcomes of mosunetuzumab use in indolent and aggressive lymphomas2025 · 1 citations
  3. 3Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study2025 · 3 citations
  4. 4Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas2025 · 1 citations
  5. 5Favorable preliminary safety and efficacy of mosunetuzumab plus ICE or DHAX salvage chemotherapy in relapsed/refractory large B-cell lymphoma2025